Dirk Thye bought $107k of QNCX
CEO AND CHIEF MEDICAL OFFICER at Quince Therapeutics, Inc.. 154,500 shares at an average of $0.70, traded Aug 29, 2024, filed Sep 3, 2024.
Score components
- +25RoleCEO
- +10Trade size$107k at market
- +6Relative to holdingsHoldings up 22%
- +8Price context50% below the 52-week high
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +8.2%, 3m +211.7%, 6m +112.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-022702, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 29, 2024 | POpen-market purchase Common Stock | +77,500 | $0.69 | $53k | 766,941 | Sep 3, 2024 |
| Aug 30, 2024 | POpen-market purchase Common Stock | +77,000 | $0.70 | $54k | 843,941 | Sep 3, 2024 |
Related signals
Other insiders at Quince Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 46Moderate | QNCXsell Quince Therapeutics, Inc. | Luca Benatti director | $174k 50,000 shares | -56% | |
| 58Moderate | Quince Therapeutics, Inc. | Charles S. Ryan PRESIDENT | $31k 48,387 shares | +65% | |
| 46Moderate | Quince Therapeutics, Inc. | Brendan Hannah CHIEF BUSINESS OFFICER AND COO | $24k 38,924 shares | +15% | |
| 36Weak | QNCXbuy Quince Therapeutics, Inc. | David Lamond director | $69k 67,881 shares | +3% | |
| 35Weak | QNCXbuy Quince Therapeutics, Inc. | David Lamond director | $58k 57,369 shares | +3% | |
| 29Weak | QNCXbuy Quince Therapeutics, Inc. | David Lamond director | $41k 43,134 shares | +2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.